Cargando…

Unexpected Outcomes of CDK4/6 Inhibition

Detalles Bibliográficos
Autores principales:	Choi, Yoon Jong, Sicinski, Piotr
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2013
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3712561/ https://www.ncbi.nlm.nih.gov/pubmed/23563596

Ejemplares similares

The transcriptome of CDK4/6 inhibition
por: Knudsen, Erik S., et al.
Publicado: (2017)

Unexpected toxicity of CDK4/6 inhibitor palbociclib and radiotherapy
por: van Aken, Evert S. M., et al.
Publicado: (2021)

CDK4/6 inhibition: the late harvest cycle begins
por: Goel, Shom, et al.
Publicado: (2016)

Inhibition of CK1ε potentiates the therapeutic efficacy of CDK4/6 inhibitor in breast cancer
por: Dang, Fabin, et al.
Publicado: (2021)

A kinase of many talents: non-neuronal functions of CDK5 in development and disease
por: Sharma, Samanta, et al.
Publicado: (2020)

CDK4/6 inhibitor: from quiescence to senescence
por: Yoshida, Akihiro, et al.
Publicado: (2015)

Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer
por: Ge, Jennifer Y., et al.
Publicado: (2020)

Unraveling the genomic determinants of response to CDK4/6 inhibitors
por: Litchfield, Lacey M., et al.
Publicado: (2018)

Increased lysosomal biomass is responsible for the resistance of triple-negative breast cancers to CDK4/6 inhibition
por: Fassl, Anne, et al.
Publicado: (2020)

CDK4/6 inhibition protects normal cells against cancer therapy-induced damage
por: Boopathi, Ettickan, et al.
Publicado: (2020)

Cyclin D1-CDK4 Controls Glucose Metabolism Independently of Cell Cycle Progression
por: Lee, Yoonjin, et al.
Publicado: (2014)

CDK4/6 inhibition in HR-positive early breast cancer: are we putting all eggs in one basket?
por: Agostinetto, Elisa, et al.
Publicado: (2020)

Is there a role for CDK 4/6 inhibitors in breast cancer brain metastases?
por: Schlam, Ilana, et al.
Publicado: (2021)

The interplay of CDK4 and CDK6 in melanoma
por: Kollmann, Karoline, et al.
Publicado: (2019)

CDK4/6 inhibition in luminal breast cancer
por: Gampenrieder, Simon Peter, et al.
Publicado: (2016)

CDK6 and p16(INK4A) in lymphoid malignancies
por: Kollmann, Karoline, et al.
Publicado: (2013)

Targeting p27 tyrosine phosphorylation as a modality to inhibit CDK4 and CDK2 and cause cell cycle arrest in breast cancer cells
por: Blain, Stacy W.
Publicado: (2018)

Inducible deletion of CDK4 and CDK6 – deciphering CDK4/6 inhibitor effects in the hematopoietic system
por: Maurer, Barbara, et al.
Publicado: (2020)

CDK4/6 inhibition triggers anti-tumor immunity
por: Goel, Shom, et al.
Publicado: (2017)

Inhibition of Mitochondrial Antioxidant Defense and CDK4/6 in Mesothelioma
por: Kratzke, Marian, et al.
Publicado: (2023)

Can ADCs broaden the treatment landscape of metastatic ER+/HER2− breast cancer resistant to CDK4/6 inhibition?
por: Van Baelen, Karen, et al.
Publicado: (2023)

Clinical CDK4/6 inhibitors induce selective and immediate dissociation of p21 from cyclin D-CDK4 to inhibit CDK2
por: Pack, Lindsey R., et al.
Publicado: (2021)

Targeting protein tyrosine phosphatases for CDK6-induced immunotherapy resistance
por: Gao, Xueliang, et al.
Publicado: (2023)

Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer
por: Al-Qasem, Abeer J., et al.
Publicado: (2022)

MicroRNA-129 Inhibits Glioma Cell Growth by Targeting CDK4, CDK6, and MDM2
por: Moradimotlagh, Atieh, et al.
Publicado: (2019)

Combined CDK2 and CDK4/6 Inhibition Overcomes Palbociclib Resistance in Breast Cancer by Enhancing Senescence
por: Pandey, Kamal, et al.
Publicado: (2020)

CDK4 phosphorylation status and rational use for combining CDK4/6 and BRAF/MEK inhibition in advanced thyroid carcinomas
por: Pita, Jaime M., et al.
Publicado: (2023)

Inhibition of CDK4/6 as a novel therapeutic option for neuroblastoma
por: Rihani, Ali, et al.
Publicado: (2015)

p18 inhibits reprogramming through inactivation of Cdk4/6
por: Zhu, Shaohua, et al.
Publicado: (2016)

CDK4/6 inhibition in cancer: the cell cycle splicing connection
por: Sheppard, Karen E., et al.
Publicado: (2019)

CDK 4/6 inhibitors for adjuvant therapy in early breast cancer—Do we have a clear winner?
por: Akhade, Amol, et al.
Publicado: (2022)

CDK4, CDK6/cyclin-D1 Complex Inhibition and Radiotherapy for Cancer Control: A Role for Autophagy
por: Nardone, Valerio, et al.
Publicado: (2021)

CDK4/6 inhibition in breast cancer: current practice and future directions
por: Pernas, Sonia, et al.
Publicado: (2018)

CDK4/6 inhibition is more active against the glioblastoma proneural subtype
por: Li, Ming, et al.
Publicado: (2017)

ATR and CDK4/6 inhibition target the growth of methotrexate-resistant choriocarcinoma
por: Georgiou, Marina, et al.
Publicado: (2022)

OR05-03 Treatment Of Parathyroid Neoplasia By Pharmacologic cdk4/6 Inhibition
por: Costa-Guda, Jessica, et al.
Publicado: (2023)

An unexpected link between immunogenic cell death and inhibition of gene transcription
por: Humeau, Juliette, et al.
Publicado: (2020)

Unexpected times
Publicado: (2020)

Expect the Unexpected!
por: Zimmerman, Karen G., et al.
Publicado: (2021)

Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degraders
por: Wu, Xuewei, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_124r30vcd4ctjjvsqtlfskarnd